Abstract: This study was supported by the European Union (Horizon 2020 and Transcan programs), the Italian Association for Cancer Research, the Italian Ministry of Health, and the Italian Ministry of University and Research.
Introduction
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by cytopenias, ineffective hematopoiesis, and a variable risk of progression to acute myeloid leukemia (AML). For over a decade, the Revised International Prognostic Scoring System (IPSS-R) has served as the clinical gold standard for risk stratification. However, the IPSS-R treats biological sex as a confounding variable rather than a fundamental driver of disease biology.
This study, published in The Lancet Haematology, challenges this paradigm. By analyzing a massive cohort of over 13,000 patients, researchers demonstrate that sex significantly influences the genotype, phenotype, and clinical trajectory of MDS. Integrating sex-specific data into prognostic models allows for a more accurate, personalized approach to patient care.
Study Design and Methodology
The researchers conducted a multicentre, observational cohort study involving 13,284 patients across four major international registries. The study utilized a combination of retrospective and prospective data to develop and validate new prognostic systems.
The methodology employed several advanced computational techniques:
- Genomic Profiling: Targeted sequencing was used to analyze mutations in 44 MDS-related genes.
- Mutation Dynamics: Bradley-Terry models estimated the temporal order of mutation acquisition, while Bayesian networks inferred conditional dependencies between specific mutations.
- Prognostic Modeling: The team developed the Sex-informed Prognostic Scoring System (PSS), which integrates sex and age with IPSS-R variables, and the Sex-informed Genomic Scoring System (GSS), which incorporates mutational data.
Genomic Sex Bias
A central finding of the study is that the molecular "starting point" of MDS differs significantly between men and women. Mutations and cytogenetic abnormalities are not distributed equally across the sexes.
Men were found to be significantly more likely to carry mutations in genes such as ASXL1, SRSF2, and ZRSR2. Conversely, women showed an enrichment for DNMT3A and TP53 mutations, as well as a higher prevalence of del(5q) abnormalities. These genomic disparities suggest that the biological mechanisms driving disease initiation and progression are sex-dependent.
Clinical Outcomes and Survival Disparities
The study confirmed that men generally face worse outcomes, with a median overall survival significantly shorter than that of women (e.g., 81.3 months vs. 123.5 months in the EuroMDS cohort). Crucially, the researchers discovered that this survival gap is primarily driven by non-leukemic death—specifically cardiac and renal complications—rather than a higher rate of AML transformation.
Furthermore, the impact of clinical markers like hemoglobin levels was found to be sex-dependent. Anemia serves as a negative prognostic factor at higher thresholds in men (<11 g/dL) compared to women (<10 g/dL), suggesting that current "one-size-fits-all" clinical thresholds may be misleading.
Improved Prognostic Accuracy and Re-stratification
The sex-informed models demonstrated superior performance compared to the traditional IPSS-R. The Sex-informed Genomic Scoring System (GSS) achieved a Concordance Index (C-index) of 0.74–0.76, compared to 0.68 for the IPSS-R.
Most importantly, the application of these new models resulted in the re-stratification of 42–56% of patients. This indicates that approximately half of the patients studied were previously assigned to inaccurate risk categories under the IPSS-R, potentially leading to suboptimal treatment decisions.
Conclusion and Future Directions
This research marks a shift toward sex-informed precision medicine in hematology. By recognizing sex as a core biological component of MDS, clinicians can better predict outcomes and tailor interventions, particularly in early-stage disease where comorbidity management is vital.
Future efforts should focus on integrating these models into prospective clinical trials and exploring the underlying biological mechanisms—such as sex hormones or X-chromosome dynamics—that drive these observed disparities. To facilitate clinical adoption, the researchers have launched a web portal for sex-informed outcome predictions.
Summary updated